Antibodies in Oncology: Drug Pipeline Update 2008

The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. Today, there are more than 190 companies plus partners developing more than 430 antibody based oncology drugs in more than 770 developmental projects. In all targeting around 50 different cancer indications. The number of antibody targets has increased to over 170 described molecular targets in just a few years. These targets are further categorized on the CD-ROM by 37 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Antibody in Oncology: Drug Pipeline Update is organized.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

* Find competitors, collaborations partners, M&A candidates etc.

* Jump start competitive drug intelligence operations

* Excellent starting point for world wide benchmarking

* Compare portfolio and therapy focus with your peers

* Speed up pro-active in-/out licensing strategy work

* Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.

Drug Pipeline Update is delivered to you as a CD-ROM application, which requires no installation on your computer. Please read more about application features and system requirements - see More..

May 2008
More...
Price: $2,350.00 / GBP1,175.00